|Free Dividend Report|
|Stock Splits Calendar|
|RGLS Stock Split History|
|Preferred Stock Newsletter|
|RGLS Options Chain|
|Stock Message Boards|
Regulus Therapeutics (RGLS) has 2 splits in our RGLS split history database. The first split for RGLS took place on October 04, 2018. This was a 1 for 12 reverse split, meaning for each 12 shares of RGLS owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 83.3333333333333 share position following the split. RGLS's second split took place on June 29, 2022. This was a 1 for 10 reverse split, meaning for each 10 shares of RGLS owned pre-split, the shareholder now owned 1 share. For example, a 83.3333333333333 share position pre-split, became a 8.33333333333333 share position following the split.
When a company such as Regulus Therapeutics conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.
Looking at the RGLS split history from start to finish, an original position size of 1000 shares would have turned into 8.33333333333333 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Regulus Therapeutics shares, starting with a $10,000 purchase of RGLS, presented on a split-history-adjusted basis factoring in the complete RGLS split history.
Growth of $10,000.00
Without Dividends Reinvested
|Average Annual Total Return:||-46.39%|
|About Regulus Therapeutics|
|Regulus Therapeutics is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat diseases. Co.'s key product candidates are RG-012 and RGLS4326. RG-012 is an anti-miR targeting miR-21 for the treatment of Alport syndrome, a life-threatening kidney disease. RGLS4326 is an anti-miR targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease. Co. has multiple programs in various stages of preclinical development including RGLS5579 as a clinical candidate in its glioblastoma multiforme program, its preclinical programs targeting the Hepatitis B virus and Non-Alcoholic Steatohepatitis program. According to our RGLS split history records, Regulus Therapeutics has had 2 splits.|
|RGLS Split History Table|
|10/04/2018||1 for 12|
|06/29/2022||1 for 10|
|Healthcare Stock Splits|
|RGLS is categorized under the Healthcare sector; below are some other companies in the same sector that also have a history of stock splits:
Also explore: RGLS shares outstanding history